Potential applications of antimicrobial peptides and their mimics in combating caries and pulpal infections

Acta Biomaterialia

Volumn 49, Issue , 2017, Pages 16-35

  Mai, Sui ^a   Mauger, Matthew T ^b   Niu, Li na ^c   Barnes, Jonathan B ^b   Kao, Solon ^b   Bergeron, Brian E ^b   Ling, Jun qi ^a   Tay, Franklin R ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b AUGUSTA UNIVERSITY   (United States)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antimicrobial peptides; Biofilms; Immunomodulation; Peptide mimics

Indexed keywords

HYDRAULIC STRUCTURES; MICROORGANISMS; NETWORK SECURITY; PEPTIDES;

ANTIMICROBIAL PEPTIDE; CATIONICS; DEFENSINS; HOST DEFENSE; IMMUNO MODULATIONS; NATURAL-ANTIMICROBIALS; ORAL CAVITY; PEPTIDE MIMICS; ROOT CANALS; WOUND HEALING;

BIOFILMS;

CYTOKINE; NISIN; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BIOMIMETIC MATERIAL;

ANTIBIOTIC RESISTANCE; BIOFILM; CYTOKINE PRODUCTION; CYTOTOXICITY; DENTAL CARIES; DRUG MECHANISM; ENDODONTICS; HEALTH; HUMAN; IMMUNE RESPONSE; MOUTH DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TOOTH INFECTION; TOOTH PULP; TOOTH ROOT CANAL; WOUND HEALING; ANIMAL; DRUG EFFECTS; IMMUNOMODULATION; MICROBIOLOGY;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOMIMETIC MATERIALS; DENTAL CARIES; DENTAL PULP; ENDODONTICS; HUMANS; IMMUNOMODULATION;

EID: 85008249118     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2016.11.026     Document Type: Review

References (222)

1. [1] Jenssen, H., Hamill, P., Hancock, R.E., Peptide antimicrobial agents. Clin. Microbiol. Rev. 19 (2006), 491–511.
2. [2] Guaní-Guerra, E., Santos-Mendoza, T., Lugo-Reyes, S.O., Terán, L.M., Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin. Immunol. 135 (2010), 1–11.
3. [3] Aoki, W., Kuroda, K., Ueda, M., Next generation of antimicrobial peptides as molecular targeted medicines. J. Biosci. Bioeng. 114 (2012), 365–370.
4. [4] Parachin, N.S., Mulder, K.C., Viana, A.A., Dias, S.C., Franco, O.L., Expression systems for heterologous production of antimicrobial peptides. Peptides 38 (2012), 446–456.
5. [5] da Silva, B.R., de Freitas, V.A., Nascimento-Neto, L.G., Carneiro, V.A., Arruda, F.V., de Aguiar, A.S., Cavada, B.S., Teixeira, E.H., Antimicrobial peptide control of pathogenic microorganisms of the oral cavity: a review of the literature. Peptides 36 (2012), 315–321.
6. [6] Auvynet, C., Rosenstein, Y., Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in innate and adaptive immunity. FEBS. J. 276 (2009), 6497–6508.
7. [7] Lai, Y., Gallo, R.L., AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 30 (2009), 131–141.
8. [8] Oudhoff, M.J., Blaauboer, M.E., Nazmi, K., Scheres, N., Bolscher, J.G., Veerman, E.C., The role of salivary histatin and the human cathelicidin LL-37 in wound healing and innate immunity. Biol. Chem. 391 (2010), 541–548.
9. [9] Steinstraesser, L., Kraneburg, U., Jacobsen, F., Al-Benna, S., Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology 216 (2011), 322–333.
10. [10] Pasupuleti, M., Schmidtchen, A., Malmsten, M., Antimicrobial peptides: key components of the innate immune system. Crit. Rev. Biotechnol. 32 (2012), 143–171.
11. [11] Choi, K.Y., Chow, L.N., Mookherjee, N., N, Cationic host defence peptides: multifaceted role in immune modulation and inflammation. J. Innate Immun. 4 (2012), 361–370.
12. [12] Figdor, D., Davies, J.K., Sundqvist, G., Starvation survival, growth and recovery of Enterococcus faecalis in human serum. Oral Microbiol. Immunol. 18 (2003), 234–239.
13. [13] Lima, S.M., de Padua, G.M., Sousa, M.G., Freire Mde, S., Franco, O.L., Rezende, T.M., Antimicrobial peptide-based treatment for endodontic infections–biotechnological innovation in endodontics. Biotechnol. Adv. 33 (2015), 203–213.
14. [14] Polanco, C., Identification of antimicrobial peptides by using eigenvectors. Acta Biochim. Pol., 2016 [Epub ahead of print].
15. [15] Wang, G., Li, X., Wang, Z., APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 44 (2016), D1087–D1093.
16. [16] Waghu, F.H., Barai, R.S., Gurung, P., Idicula-Thomas, S., CAMPR3: a database on sequences, structures and signatures of antimicrobial peptides. Nucleic Acids Res. 44 (2016), D1094–D1097.
17. [17] Pirtskhalava, M., Gabrielian, A., Cruz, P., Griggs, H.L., Squires, R.B., Hurt, D.E., Grigolava, M., Chubinidze, M., Gogoladze, G., Vishnepolsky, B., Alekseyev, V., Rosenthal, A., Tartakovsky, M., DBAASP v. 2: an enhanced database of structure and antimicrobial/cytotoxic activity of natural and synthetic peptides. Nucleic Acids Res. 44 (2016), D1104–D1112.
18. [18] De Smet, K., Contreras, R., Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol. Lett. 27 (2005), 1337–1347.
19. [19] Hancock, R.E., Sahl, H.G., Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24 (2006), 1551–1557.
20. [20] Nakatsuji, T., Gallo, R.L., Antimicrobial peptides: old molecules with new ideas. J. Invest. Dermatol. 132 (2012), 887–895.
21. [21] Meyer-Hoffert, U., Schwarz, T., Schröder, J.M., Gläser, R., Increased expression of human beta-defensin 3 in mollusca contagiosum. Clin. Exp. Dermatol. 35 (2010), 190–192.
22. [22] Conner, K., Nern, K., Rudisill, J., O'Grady, T., Gallo, R.L., The antimicrobial peptide LL-37 is expressed by keratinocytes in condyloma acuminatum and verruca vulgaris. J. Am. Acad. Dermatol. 47 (2002), 347–350.
23. [23] Kreuter, A., Jaouhar, M., Skrygan, M., Tigges, C., Stücker, M., Altmeyer, P., Gläser, R., Gambichler, T., Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 65 (2011), 125–133.
24. [24] Frasca, L., Lande, R., Role of defensins and cathelicidin LL37 in auto-immune and auto-inflammatory diseases. Curr. Pharm. Biotechnol. 13 (2012), 1882–1897.
25. [25] Chandrudu, S., Simerska, P., Toth, I., Chemical methods for peptide and protein production. Molecules 18 (2013), 4373–4388.
26. [26] Ebenhan, T., Gheysens, O., Kruger, H.G., Zeevaart, J.R., Sathekge, M.M., Antimicrobial peptides: their role as infection-selective tracers for molecular imaging. Biomed. Res. Int., 2014, 2014, 867381.
27. [27] Yeaman, M.R., Yount, N.Y., Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev. 55 (2003), 27–55.
28. [28] Brouwer, C.P., Wulferink, M., Welling, M.M., The pharmacology of radiolabeled cationic antimicrobial peptides. J. Pharm. Sci. 97 (2008), 1633–1651.
29. [29] Epand, R.M., Vogel, H.J., Diversity of antimicrobial peptides and their mechanisms of action. Biochim. Biophys. Acta 1462 (1999), 11–28.
30. [30] Zhang, L., Rozek, A., Hancock, R.E., Interaction of cationic antimicrobial peptides with model membranes. J. Biol. Chem. 276 (2001), 35714–35722.
31. [31] Takahashi, D., Shukla, S.K., Prakash, O., Zhang, G., Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity. Biochimie 92 (2010), 1236–1241.
32. [32] Giangaspero, A., Sandri, L., Tossi, A., Amphipathic alpha helical antimicrobial peptides. Eur. J. Biochem. 268 (2001), 5589–5600.
33. [33] Dathe, M., Wieprecht, T., Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim. Biophys. Acta 1462 (1999), 71–87.
34. [34] Brogden, K.A., Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat. Rev. Microbiol. 3 (2005), 238–250.
35. [35] Teixeira, V., Feio, M.J., Bastos, M., Role of lipids in the interaction of antimicrobial peptides with membranes. Prog. Lipid Res. 51 (2012), 149–177.
36. [36] Malanovic, N., Lohner, K., Gram-positive bacterial cell envelopes: The impact on the activity of antimicrobial peptides. Biochim. Biophys. Acta. 2016 (1858), 936–946.
37. [37] Chen, X., Hirt, H., Li, Y., Gorr, S.U., Aparicio, C., Antimicrobial GL13K peptide coatings killed and ruptured the wall of Streptococcus gordonii and prevented formation and growth of biofilms. PLoS ONE, 9, 2014, e111579.
38. [38] Weidenmaier, C., Peschel, A., Teichoic acids and related cell-wall glycopolymers in Gram- positive physiology and host interactions. Nature Rev. Microbiol. 6 (2008), 276–287.
39. [39] Di Luca, M., Maccari, G., Nifosì, R., Treatment of microbial biofilms in the post-antibiotic era: prophylactic and therapeutic use of antimicrobial peptides and their design by bioinformatics tools. Pathog. Dis. 70 (2014), 257–270.
40. [40] Zasloff, M., Antimicrobial peptides of multicellular organisms. Nature 415 (2002), 389–395.
41. [41] Amerongen, A.V., Veerman, E.C., Saliva - the defender of the oral cavity. Oral Dis. 8 (2002), 12–22.
42. [42] Gorr, S.U., Abdolhosseini, M., Antimicrobial peptides and periodontal disease. J. Clin. Periodontol. 38:Suppl 11 (2011), 126–141.
43. [43] Devine, D.A., Cosseau, C., Host defense peptides in the oral cavity. Adv. Appl. Microbiol. 63 (2008), 281–322.
44. [44] Dale, B.A., Tao, R., Kimball, J.R., Jurevic, R.J., Oral antimicrobial peptides and biological control of caries. BMC Oral Health., 6(Suppl 1), 2006, S13.
45. [45] Khurshid, Z., Naseem, M., Sheikh, Z., Najeeb, S., Shahab, S., Zafar, M.S., Oral antimicrobial peptides: Types and role in the oral cavity. Saudi Pharm. J., 2015, 10.1016/j.jsps.2015.02.015 in press.
46. [46] Yang, D., Biragyn, A., Hoover, D.M., Lubkowski, J., Oppenheim, J.J., Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu. Rev. Immunol. 22 (2004), 181–215.
47. [47] Baumgartner, J.C., Falkler, W.A. Jr, Bacteria in the apical 5 mm of infected root canals. J. Endod. 17 (1991), 380–383.
48. [48] Silva, M.J., Kajiya, M., AlShwaimi, E., Sasaki, H., Hong, J., Ok, P., Rezende, T.M., Pagonis, T.C., White, R.R., Paster, B.J., Stashenko, P., Kawai, T., Bacteria-reactive immune response may induce RANKL-expressing T cells in the mouse periapical bone loss lesion. J. Endod. 38 (2012), 346–350.
49. [49] Stashenko, P., Teles, R., D'Souza, R., Periapical inflammatory responses and their modulation. Crit. Rev. Oral Biol. Med. 9 (1998), 498–521.
50. [50] Torabinejad, M., Eby, W.C., Naidorf, I.J., Inflammatory and immunological aspects of the pathogenesis of human periapical lesions. J. Endod. 11 (1985), 479–488.
51. [51] van Winkelhoff, A.J., Herrera, D., Winkel, E.G., Dellemijn-Kippuw, N., Vandenbroucke-Grauls, C.M., Sanz, M., Antibiotic resistance in the subgingival microflora in patients with adult periodontitis. A comparative survey between Spain and the Netherlands. Ned. Tijdschr. Tandheelkd. 106 (1999), 290–294.
52. [52] Ready, D., Bedi, R., Spratt, D.A., Mullany, P., Wilson, M., Prevalence, proportions, and identities of antibiotic-resistant bacteria in the oral microflora of healthy children. Microb. Drug. Resist. 9 (2003), 367–372.
53. [53] Sweeney, L.C., Dave, J., Chambers, P.A., Heritage, J., Antibiotic resistance in general dental practice–a cause for concern?. J. Antimicrob. Chemother. 53 (2004), 567–576.
54. [54] Lancaster, H., Bedi, R., Wilson, M., Mullany, P., The maintenance in the oral cavity of children of tetracycline-resistant bacteria and the genes encoding such resistance. J. Antimicrob. Chemother. 56 (2005), 524–531.
55. [55] Diaz-Torres, M.L., Villedieu, A., Hunt, N., McNab, R., Spratt, D.A., Allan, E., Mullany, P., Wilson, M., Determining the antibiotic resistance potential of the indigenous oral microbiota of humans using a metagenomic approach. FEMS Microbiol. Lett. 258 (2006), 257–262.
56. [56] Al-Haroni, M., Bacterial resistance and the dental professionals’ role to halt the problem. J. Dent. 36 (2008), 95–103.
57. [57] Kouidhi, B., Zmantar, T., Mahdouani, K., Hentati, H., Bakhrouf, A., Antibiotic resistance and adhesion properties of oral Enterococci associated to dental caries. BMC Microbiol., 11, 2011, 155.
58. [58] Soares, G.M., Figueiredo, L.C., Faveri, M., Cortelli, S.C., Duarte, P.M., Feres, M., Mechanisms of action of systemic antibiotics used in periodontal treatment and mechanisms of bacterial resistance to these drugs. J. Appl. Oral Sci. 20 (2012), 295–309.
59. [59] Koukos, G., Papadopoulos, C., Tsalikis, L., Sakellari, D., Arsenakis, M., Konstantinidis, A., Prevalence of antibiotic resistance genes in subjects with successful and failing dental implants. A pilot study, Open. Dent. J. 8 (2015), 257–263.
60. [60] Koukos, G., Konstantinidis, A., Tsalikis, L., Arsenakis, M., Slini, T., Sakellari, D., Prevalence of β-lactam (bla TEM) and metronidazole (nim) resistance genes in the oral cavity of Greek subjects. Open Dent. J. 10 (2016), 89–98.
61. [61] Bos, J., Hopman, M.M., Stuiver, A., Voss, Decolonisation of meticillin-resistant Staphylococcus aureus (MRSA) carriage in adopted children with cleft lip and palate. J. Glob. Antimicrob. Resist. 7 (2016), 28–33.
62. [62] Huo, L., Zhang, K., Ling, J., Peng, Z., Huang, X., Liu, H., Gu, L., Antimicrobial and DNA-binding activities of the peptide fragments of human lactoferrin and histatin 5 against Streptococcus mutans. Arch. Oral Biol. 56 (2011), 869–876.
63. [63] Liu, H., Xu, Q., Huo, L., Wei, X., Ling, J., Chemical composition of Enterococcus faecalis in biofilm cells initiated from different physiologic states. Folia Microbiol (Praha). 59 (2014), 447–453.
64. [64] Ebrahem, M.A., Expression of human beta defensins (HBDs) 1, 2 and 3 in gingival crevicular fluid of patients affected by localized aggressive periodontitis. Saudi Dent. J. 25 (2013), 75–82.
65. [65] Gao, G., Lange, D., Hilpert, K., Kindrachuk, J., Zou, Y., Cheng, J.T., Kazemzadeh-Narbat, M., Yu, K., Wang, R., Straus, S.K., Brooks, D.E., Chew, B.H., Hancock, R.E., Kizhakkedathu, J.N., The biocompatibility and biofilm resistance of implant coatings based on hydrophilic polymer brushes conjugated with antimicrobial peptides. Biomaterials 32 (2011), 3899–3909.
66. [66] Hua, J., Yamarthy, R., Felsenstein, S., Scott, R.W., Markowitz, K., Diamond, G., Activity of antimicrobial peptide mimetics in the oral cavity: I. Activity against biofilms of Candida albicans. Mol. Oral Microbiol. 25 (2010), 418–425.
67. [67] Batoni, G., Maisetta, G., Esin, S., Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. Biochim. Biophys. Acta. 2016 (1858), 1044–1060.
68. [68] Hancock, R.E., The therapeutic potential of cationic peptides. Expert Opin. Investig. Drugs 7 (1998), 167–174.
69. [69] Jerala, R., Porro, M., Endotoxin neutralizing peptides. Curr. Top. Med. Chem. 4 (2004), 1173–1184.
70. [70] Abiko, Y., Saitoh, M., Salivary defensins and their importance in oral health and disease. Curr. Pharm. Des. 13 (2007), 3065–3072.
71. [71] Pepperney, A., Chikindas, M.L., Antibacterial peptides: Opportunities for the prevention and treatment of dental caries. Probiotics Antimicrob. Proteins, 3, 2011, 68.
72. [72] Goldman, M.J., Anderson, G.M., Stolzenberg, E.D., Kari, U.P., Zasloff, M., Wilson, J.M., Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88 (1997), 553–560.
73. [73] Nagaoka, I., Hirota, S., Yomogida, S., Ohwada, A., Hirata, M., Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm. Res. 49 (2000), 73–79.
74. [74] Turner, J., Cho, Y., Dinh, N.N., Waring, A.J., Lehrer, R.I., Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob. Agents Chemother. 42 (1998), 2206–2214.
75. [75] Dale, B.A., Fredericks, L.P., Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr. Issues Mol. Biol. 7 (2005), 119–133.
76. [76] Joly, S., Maze, C., Jr McCray, P.B., Guthmiller, J.M., Human-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J. Clin. Microbiol. 42 (2004), 1024–1029.
77. [77] Song, W., Shi, Y., Xiao, M., Lu, H., Qu, T., Li, P., Wu, G., Tian, Y., In vitro bactericidal activity of recombinant human beta-defensin-3 against pathogenic bacterial strains in human tooth root canal. Int. J. Antimicrob. Agents 33 (2009), 237–243.
78. [78] Lundy, F.T., Nelson, J., Lockhart, D., Greer, B., Harriott, P., Marley, J.J., Antimicrobial activity of truncated alpha-defensin (human neutrophil peptide (HNP)-1) analogues without disulphide bridges. Mol. Immunol. 45 (2008), 190–193.
79. [79] Ji, S., Hyun, J., Park, E., Lee, B.L., Kim, K.K., Choi, Y., Susceptibility of various oral bacteria to antimicrobial peptides and to phagocytosis by neutrophils. J. Periodontal Res. 42 (2007), 410–419.
80. [80] Lee, S.H., Baek, D.H., Antibacterial and neutralizing effect of human beta-defensins on Enterococcus faecalis and Enterococcus faecalis lipoteichoic acid. J. Endod. 38 (2012), 351–356.
81. [81] Lee, J.K., Park, Y.J., Kum, K.Y., Han, S.H., Chang, S.W., Kaufman, B., Jiang, J., Zhu, Q., Safavi, K., Spångberg, L., Antimicrobial efficacy of a human beta-defensin-3 peptide using an Enterococcus faecalis dentine infection model. Int. Endod. J. 46 (2013), 406–412.
82. [82] Shimotoyodome, A., Kobayashi, H., Tokimitsu, I., Matsukubo, T., Takaesu, Y., Statherin and histatin 1 reduce parotid saliva-promoted Streptococcus mutans strain MT8148 adhesion to hydroxyapatite surfaces. Caries Res. 40 (2006), 403–411.
83. [83] Vukosavljevic, D., Custodio, W., Del Bel Cury, A.A., Siqueira, W.L., The effect of histatin 5, adsorbed on PMMA and hydroxyapatite, on Candida albicans colonization. Yeast 29 (2012), 459–466.
84. [84] Rothstein, D.M., Spacciapoli, P., Tran, L.T., Xu, T., Roberts, F.D., Dalla Serra, M., Buxton, D.K., Oppenheim, F.G., Friden, P., Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Antimicrob. Agents Chemother. 45 (2001), 1367–1373.
85. [85] Sajjan, U.S., Tran, L.T., Sole, N., Rovaldi, C., Akiyama, A., Friden, P.M., Forstner, J.F., Rothstein, D.M., P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob. Agents Chemother. 45 (2001), 3437–3444.
86. [86] Rosen, G., Sela, M.N., Bachrach, G., The antibacterial activity of LL-37 against Treponema denticola is dentilisin protease independent and facilitated by the major outer sheath protein virulence factor. Infect. Immun. 80 (2012), 1107–1114.
87. [87] Thennarasu, S., Tan, A., Penumatchu, R., Shelburne, C.E., Heyl, D.L., Ramamoorthy, A., Antimicrobial and membrane disrupting activities of a peptide derived from the human cathelicidin antimicrobial peptide LL37. Biophys. J. 98 (2010), 248–257.
88. [88] Overhage, J., Campisano, A., Bains, M., Torfs, E.C., Rehm, B.H., Hancock, R.E., Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 76 (2008), 4176–4182.
89. [89] Augustyniak, D., Nowak, J., Lundy, F.T., Direct and indirect antimicrobial activities of neuropeptides and their therapeutic potential. Curr. Protein Pept. Sci. 13 (2012), 723–738.
90. [90] El Karim, I.A., Linden, G.J., Orr, D.F., Lundy, F.T., Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites. J. Neuroimmunol. 200 (2008), 11–16.
91. [91] Awawdeh, L., Lundy, F.T., Shaw, C., Lamey, P.J., Linden, G.J., Kennedy, J.G., Quantitative analysis of substance P, neurokinin A and calcitonin gene-related peptide in pulp tissue from painful and healthy human teeth. Int. Endod. J. 35 (2002), 30–36.
92. [92] El Karim, I.A., Lamey, P.J., Ardill, J., Linden, G.J., Lundy, F.T., Vasoactive intestinal polypeptide (VIP) and VPAC1 receptor in adult human dental pulp in relation to caries. Arch. Oral Biol. 51 (2006), 849–855.
93. [93] El Karim, I.A., Lamey, P.J., Linden, G.J., Awawdeh, L.A., Lundy, F.T., Caries-induced changes in the expression of pulpal neuropeptide Y. Eur. J. Oral Sci. 114 (2006), 133–137.
94. [94] Arslan, S.Y., Leung, K.P., Wu, C.D., The effect of lactoferrin on oral bacterial attachment. Oral Microbiol. Immunol. 24 (2009), 411–416.
95. [95] Batoni, Y.J., Romanowski, E.G., McDermott, A.M., A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res. 30 (2005), 505–515.
96. [96] He, Y., He, X., Molecular design and genetic optimization of antimicrobial peptides containing unnatural amino acids against antibiotic-resistant bacterial infections. Biopolymers, 2016, 10.1002/bip.22885 Epub ahead of print.
97. [97] Hadley, E.B., Hancock, R.E., Strategies for the discovery and advancement of novel cationic antimicrobial peptides. Curr. Top Med. Chem. 10 (2010), 1872–1881.
98. [98] Brogden, N.K., Brogden, K.A., Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?. Int. J. Antimicrob. Agents. 38 (2011), 217–225.
99. [99] Seo, M.D., Won, H.S., Kim, J.H., Mishig-Ochir, T., Lee, B.J., Antimicrobial peptides for therapeutic applications: a review. Molecules 17 (2012), 12276–12286.
100. [100] Fjell, C.D., Hiss, J.A., Hancock, R.E., Schneider, G., Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 11 (2011), 37–51.
101. [101] Kang, S.J., Park, S.J., Mishig-Ochir, T., Lee, B.J., Antimicrobial peptides: therapeutic potentials. Expert. Rev. Anti. Infect Ther. 12 (2014), 1477–1486.
102. [102] Carmona-Ribeiro, A.M., de Melo Carrasco, L.D., Novel formulations for antimicrobial peptides. Int. J. Mol. Sci. 15 (2014), 18040–18083.
103. [103] Maccari, G., Di Luca, M., Nifosì, R., In silico design of antimicrobial peptides. Methods Mol. Biol. 1268 (2015), 195–219.
104. [104] Reinhardt, A., Neundorf, I., Design and application of antimicrobial peptide conjugates. Int. J. Mol. Sci., 17, 2016, 701.
105. [105] Haug, B.E., Stensen, W., Kalaaji, M., Rekdal, Ø., Svendsen, J.S., Synthetic antimicrobial peptidomimetics with therapeutic potential. J. Med. Chem. 51 (2008), 4306–4314.
106. [106] Niu, Y., Wang, R.E., Wu, H., Cai, J., Recent development of small antimicrobial peptidomimetics. Future Med. Chem. 4 (2012), 1853–1862.
107. [107] Méndez-Samperio, P., Peptidomimetics as a new generation of antimicrobial agents: current progress. Infect. Drug Resist. 7 (2014), 229–237.
108. [108] Winfred, S.B., Meiyazagan, G., Panda, J.J., Nagendrababu, V., Deivanayagam, K., Chauhan, V.S., Venkatraman, G., Antimicrobial activity of cationic peptides in endodontic procedures. Eur. J. Dent. 8 (2014), 254–260.
109. [109] Liu, Y., Wang, L., Zhou, X., Hu, S., Zhang, S., Wu, H., Effect of the antimicrobial decapeptide KSL on the growth of oral pathogens and Streptococcus mutans biofilm. Int. J. Antimicrob. Agents. 37 (2011), 33–38.
110. [110] Beckloff, N., Laube, D., Castro, T., Furgang, D., Park, S., Perlin, D., Clements, D., Tang, H., Scott, R.W., Tew, G.N., Diamond, G., Activity of an antimicrobial peptide mimetic against planktonic and biofilm cultures of oral pathogens. Antimicrob. Agents Chemother. 51 (2007), 4125–4132.
111. [111] da Silva, B.R., de Freitas, V.A., Carneiro, V.A., Arruda, F.V., Lorenzón, E.N., de Aguiar, A.S., Cilli, E.M., Cavada, B.S., Teixeira, E.H., Antimicrobial activity of the synthetic peptide Lys-a1 against oral streptococci. Peptides 42 (2013), 78–83.
112. [112] Eckhard, L.H., Sol, A., Abtew, E., Shai, Y., Domb, A.J., Bachrach, G., Beyth, N., Biohybrid polymer-antimicrobial peptide medium against Enterococcus faecalis. PLoS ONE, 9, 2014, e109413.
113. [113] Bowdish, D.M., Davidson, D.J., Scott, M.G., Hancock, R.E., Immunomodulatory activities of small host defense peptides. Antimicrob. Agents Chemother. 49 (2005), 1727–1732.
114. [114] Wu, M., Hancock, R.E., Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J. Biol. Chem. 274 (1999), 29–35.
115. [115] Haney, E.F., Hunter, H.N., Matsuzaki, K., Vogel, H.J., Solution NMR studies of amphibian antimicrobial peptides: linking structure to function?. Biochim. Biophys. Acta. 1788 (2009), 1639–1655.
116. [116] Nijnik, A., Madera, L., Ma, S., Waldbrook, M., Elliott, M.R., Easton, D.M., Mayer, M.L., Mullaly, S.C., Kindrachuk, J., Jenssen, H., Hancock, R.E., Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J. Immunol. 18 (2010), 2539–2550.
117. [117] Pena, O.M., Afacan, N., Pistolic, J., Chen, C., Madera, L., Falsafi, R., Fjell, C.D., Hancock, R.E., Synthetic cationic peptide IDR-1018 modulates human macrophage differentiation. PLoS ONE, 8, 2013, e52449.
118. [118] Wieczorek, M., Jenssen, H., Kindrachuk, J., Scott, W.R., Elliott, M., Hilpert, K., Cheng, J.T., Hancock, R.E., Straus, S.K., Structural studies of a peptide with immune modulating and direct antimicrobial activity. Chem. Biol. 17 (2010), 970–980.
119. [119] Avrahami, D., Shai, Y., A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid. J. Biol. Chem. 279 (2004), 12277–12285.
120. [120] Stromstedt, A.A., Pasupuleti, M., Schmidtchen, A., Malmsten, M., Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. Antimicrob. Agents Chemother. 53 (2009), 593–602.
121. [121] Hilpert, K., Volkmer-Engert, R., Walter, T., Hancock, R.E., High-throughput generation of small antibacterial peptides with improved activity. Nat. Biotechnol. 23 (2005), 1008–1012.
122. [122] Ding, Y., Wang, W., Fan, M., Tong, Z., Kuang, R., Jiang, W., Ni, L., Antimicrobial and anti-biofilm effect of Bac8c on major bacteria associated with dental caries and Streptococcus mutans biofilms. Peptides 52 (2014), 61–67.
123. [123] Mansour, S.C., de la Fuente-Núñez, C., Hancock, R.E., Peptide IDR-1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections. J. Pept. Sci. 21 (2015), 323–329.
124. [124] Choe, H., Narayanan, A.S., Gandhi, D.A., Weinberg, A., Marcus, R.E., Lee, Z., Bonomo, R.A., Greenfield, E.M., Immunomodulatory peptide IDR-1018 decreases implant infection and preserves osseointegration. Clin. Orthop. Relat. Res. 473 (2015), 2898–2907.
125. [125] Niyonsaba, F., Madera, L., Afacan, N., Okumura, K., Ogawa, H., Hancock, R.E., The innate defense regulator peptides IDR-HH2, IDR-1002, and IDR-1018 modulate human neutrophil functions. J. Leukoc. Biol. 94 (2013), 159–170.
126. [126] Wang, Z., de la Fuente-Nunez, C., Shen, Y., Haapasalo, M., Hancock, R.E., Treatment of oral multispecies biofilms by an anti-biofilm peptide. PLoS ONE, 10, 2015, e0132512.
127. [127] Marsh, P.D., Microbial ecology of dental plaque and its significance in health and disease. Adv. Dent. Res. 8 (1994), 263–271.
128. [128] Marsh, P.D., Dental plaque as a microbial biofilm. Caries Res. 38 (2004), 204–211.
129. [129] Eckert, R., He, J., Yarbrough, D.K., Qi, F., Anderson, M.H., Shi, W., Targeted killing of Streptococcus mutans by a pheromone-guided “smart” antimicrobial peptide. Antimicrob. Agents Chemother. 50 (2006), 3651–3657.
130. [130] He, J., Yarbrough, D.K., Kreth, J., Anderson, M.H., Shi, W., Eckert, R., Systematic approach to optimizing specifically Targeted Antimicrobial Peptides against Streptococcus mutans. Antimicrob. Agents Chemother. 54 (2010), 2143–2151.
131. [131] Kaplan, C.W., Sim, J.H., Shah, K.R., Kolesnikova-Kaplan, A., Shi, W., Eckert, R., Selective membrane disruption: mode of action of C16G2, a specifically targeted antimicrobial peptide. Antimicrob. Agents Chemother. 55 (2011), 3446–3452.
132. [132] Eckert, R., Sullivan, R., Shi, W., Targeted antimicrobial treatment to re-establish a healthy microbial flora for long-term protection. Adv. Dent. Res. 24 (2012), 94–97.
133. [133] Guo, L., McLean, J.S., Yang, Y., Eckert, R., Kaplan, C.W., Kyme, P., Sheikh, O., Varnum, B., Lux, R., Shi, W., He, X., Precision-guided antimicrobial peptide as a targeted modulator of human microbial ecology. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 7569–7574.
134. [134] Sullivan, R., Santarpia, P., Lavender, S., Gittins, E., Liu, Z., Anderson, M.H., He, J., Shi, W., Eckert, R., Clinical efficacy of a specifically targeted antimicrobial peptide mouth rinse: targeted elimination of Streptococcus mutans and prevention of demineralization. Caries Res. 45 (2011), 415–428.
135. [135] Sundqvist, G., Figdor, D., Life as an endodontic pathogen. Etiological differences between untreated and root-filled root canals. Endod. Topics 6 (2003), 3–28.
136. [136] Jr Siqueira, J.F., Rôças, I.N., Diversity of endodontic microbiota revisited. J. Dent. Res. 88 (2009), 969–981.
137. [137] Parahitiyawa, N.B., Chu, F.C., Leung, W.K., Yam, W.C., Jin, L.J., Samaranayake, L.P., Clonality of bacterial consortia in root canals and subjacent gingival crevices. J. Investig. Clin. Dent. 6 (2015), 32–39.
138. [138] Molander, A., Reit, C., Dahlén, G., Kvist, T., Microbiological status of root-filled teeth with apical periodontitis. Int. Endod. J. 31 (1998), 1–7.
139. [139] Sundqvist, G., Figdor, D., Persson, S., Sjögren, U., Microbiologic analysis of teeth with failed endodontic treatment and the outcome of conservative re-treatment. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 85 (1998), 86–93.
140. [140] Murad, C.F., Sassone, L.M., Faveri, M., Jr Hirata, R., Figueiredo, L., Feres, M., Microbial diversity in persistent root canal infections investigated by checkerboard DNA-DNA hybridization. J. Endod. 40 (2014), 899–906.
141. [141] Gharsallaoui, A., Oulahal, N., Joly, C., Degraeve, P., Nisin as a food preservative: Part 1: Physicochemical properties, antimicrobial activity, and main uses. Crit. Rev. Food Sci. Nutr. 56 (2016), 1262–1274.
142. [142] Gharsallaoui, A., Joly, C., Oulahal, N., Degraeve, P., Nisin as a food preservative: Part 2: Antimicrobial polymer materials containing nisin. Crit. Rev. Food Sci. Nutr. 56 (2016), 1275–1289.
143. [143] Fernandez, L., Delgado, S., Herrero, H., Maldonado, A., Rodríguez, J.M., The bacteriocin nisin, an effective agent for the treatment of staphylococcal mastitis during lactation. J. Hum. Lact. 24 (2008), 311–316.
144. [144] Valenta, C., Bernkop-Schnurch, A., Rigler, H.P., The antistaphylococcal effect of nisin in a suitable vehicle: a potential therapy for atopic dermatitis in man. J. Pharm. Pharmacol. 48 (1996), 988–991.
145. [145] De Kwaadsteniet, M., Doeschate, K.T., Dicks, L.M., Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus. Lett. Appl. Microbiol. 48 (2009), 65–70.
146. [146] Tong, Z., Dong, L., Zhou, L., Tao, R., Ni, L., Nisin inhibits dental caries-associated microorganism in vitro. Peptides 31 (2010), 2003–2008.
147. [147] Shin, J.M., Ateia, I., Paulus, J.R., Liu, H., Fenno, J.C., Rickard, A.H., Kapila, Y.L., Antimicrobial nisin acts against saliva derived multi-species biofilms without cytotoxicity to human oral cells. Front. Microbiol., 6, 2015, 617.
148. [148] Tong, Z., Zhou, L., Jiang, W., Kuang, R., Li, J., Tao, R., Ni, L., An in vitro synergetic evaluation of the use of nisin and sodium fluoride or chlorhexidine against Streptococcus mutans. Peptides 32 (2011), 2021–2026.
149. [149] Tong, Z., Zhang, L., Ling, J., Jian, Y., Huang, L., Deng, D., An in vitro study on the effect of free amino acids alone or in combination with nisin on biofilms as well as on planktonic bacteria of Streptococcus mutans. PLoS ONE, 9, 2014, e99513.
150. [150] Turner, S.R., Love, R.M., Lyons, K.M., An in-vitro investigation of the antibacterial effect of nisin in root canals and canal wall radicular dentine. Int. Endod. J. 37 (2004), 664–671.
151. [151] Tong, Z., Huang, L., Ling, J., Mao, X., Ning, Y., Deng, D., Effects of intracanal irrigant MTAD Combined with nisin at sub-minimum inhibitory concentration levels on Enterococcus faecalis growth and the expression of pathogenic genes. PLoS ONE, 9, 2014, e90235.
152. [152] Tong, Z., Ling, J., Lin, Z., Li, X., Mu, Y., The effect of MTADN on 10 Enterococcus faecalis isolates and biofilm: an in vitro study. J. Endod. 39 (2013), 674–678.
153. [153] Tong, Z., Zhou, L., Kuang, R., Lv, H., Qu, T., Ni, L., In vitro evaluation of MTAD and nisin in combination against common pathogens associated with root canal infection. J. Endod. 38 (2012), 490–494.
154. [154] Tong, Z., Zhou, L., Li, J., Jiang, W., Ma, L., Ni, L., In vitro evaluation of the antibacterial activities of MTAD in combination with nisin against Enterococcus faecalis. J. Endod. 37 (2011), 1116–1120.
155. [155] Stevens, K.A., Sheldon, B.W., Klapes, N.A., Klaenhammer, T.R., Nisin treatment for inactivation of Salmonella species and other gram-negative bacteria. Appl. Environ. Microbiol. 57 (1991), 3613–3615.
156. [156] Tong, Z., Zhang, Y., Ling, J., Ma, J., Huang, L., Zhang, L., An in vitro study on the effects of nisin on the antibacterial activities of 18 antibiotics against Enterococcus faecalis. PLoS ONE, 9, 2014, e89209.
157. [157] Diamond, G., Ryan, L., Beta-defensins: what are they really doing in the oral cavity?. Oral Dis. 17 (2011), 628–635.
158. [158] Krisanaprakornkit, S., Kimball, J.R., Weinberg, A., Darveau, R.P., Bainbridge, B.W., Dale, B.A., Inducible expression of human beta-defensin 2 by Fusobacterium nucleatum in oral epithelial cells: multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. Infect. Immun. 68 (2000), 2907–2915.
159. [159] Kim, Y.S., Min, K.S., Lee, S.I., Shin, S.J., Shin, K.S., Kim, E.C., Effect of proinflammatory cytokines on the expression and regulation of human beta-defensin 2 in human dental pulp cells. J. Endod. 36 (2010), 64–69.
160. [160] Lee, S.I., Min, K.S., Bae, W.J., Lee, Y.M., Lee, S.Y., Lee, E.S., Kim, E.C., Role of SIRT1 in heat stress- and lipopolysaccharide-induced immune and defense gene expression in human dental pulp cells. J. Endod. 37 (2011), 1525–1530.
161. [161] Horst, O.V., Horst, J.A., Samudrala, R., Dale, B.A., Caries induced cytokine network in the odontoblast layer of human teeth. BMC Immunol., 12, 2011, 9.
162. [162] Paris, S., Wolgin, M., Kielbassa, A.M., Pries, A., Zakrzewicz, A., Gene expression of human beta-defensins in healthy and inflamed human dental pulps. J. Endod. 35 (2009), 520–523.
163. [163] Lee, S.I., Kang, S.K., Jung, H.J., Chun, Y.H., Kwon, Y.D., Kim, E.C., Muramyl dipeptide activates human beta defensin 2 and pro-inflammatory mediators through Toll-like receptors and NLRP3 inflammasomes in human dental pulp cells. Clin. Oral Investig. 19 (2015), 1419–1428.
164. [164] Bowdish, D.M., Davidson, D.J., Hancock, R.E., Immunomodulatory properties of defensins and cathelicidins. Curr. Top Microbiol. Immunol. 306 (2006), 27–66.
165. [165] Koczulla, R., von Degenfeld, G., Kupatt, C., Krötz, F., Zahler, S., Gloe, T., Issbrücker, K., Unterberger, P., Zaiou, M., Lebherz, C., Karl, A., Raake, P., Pfosser, A., Boekstegers, P., Welsch, U., Hiemstra, P.S., Vogelmeier, C., Gallo, R.L., Clauss, M., Bals, R., An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 111 (2003), 1665–1672.
166. [166] Carretero, M., Escamez, M.J., Garcia, M., Duarte, B., Holguin, A., Retamosa, L., Jorcano, J.L., Río, M.D., Larcher, F., In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J. Invest. Dermatol. 128 (2008), 223–236.
167. [167] Supanchart, C., Thawanaphong, S., Makeudom, A., Bolscher, J.G., Nazmi, K., Kornak, U., Krisanaprakornkit, S., The antimicrobial peptide, LL-37, inhibits in vitro osteoclastogenesis. J. Dent. Res. 91 (2012), 1071–1077.
168. [168] Kajiya, M., Shiba, H., Komatsuzawa, H., Ouhara, K., Fujita, T., Takeda, K., Uchida, Y., Mizuno, N., Kawaguchi, H., Kurihara, H., The antimicrobial peptide LL37 induces the migration of human pulp cells: a possible adjunct for regenerative endodontics. J. Endod. 36 (2010), 1009–1013.
169. [169] Khung, R., Shiba, H., Kajiya, M., Kittaka, M., Ouhara, K., Takeda, K., Mizuno, N., Fujita, T., Komatsuzawa, H., Kurihara, H., LL37 induces VEGF expression in dental pulp cells through ERK signalling. Int. Endod. J. 48 (2015), 673–679.
170. [170] Edgerton, M., Koshlukova, S.E., Salivary histatin 5 and its similarities to the other antimicrobial proteins in human saliva. Adv. Dent. Res. 14 (2000), 16–21.
171. [171] Oppenheim, F.G., Salih, E., Siqueira, W.L., Zhang, W., Helmerhorst, E.J., Salivary proteome and its genetic polymorphisms. Ann. N. Y. Acad. Sci. 1098 (2007), 22–50.
172. [172] Driscoll, J., Zuo, Y., Xu, T., Choi, J.R., Troxler, R.F., Oppenheim, F.G., Functional comparison of native and recombinant human salivary histatin 1. J. Dent. Res. 74 (1995), 1837–1844.
173. [173] Azzopardi, P.V., O'Young, J., Lajoie, G., Karttunen, M., Goldberg, H.A., Hunter, G.K., Roles of electrostatics and conformation in protein-crystal interactions. PLoS ONE, 5, 2010, e9330.
174. [174] Siqueira, W.L., Margolis, H.C., Helmerhorst, E.J., Mendes, F.M., Oppenheim, F.G., Evidence of intact histatins in the in vivo acquired enamel pellicle. J. Dent. Res. 89 (2010), 626–630.
175. [175] McDonald, E.E., Goldberg, H.A., Tabbara, N., Mendes, F.M., Siqueira, W.L., Histatin 1 resists proteolytic degradation when adsorbed to hydroxyapatite. J. Dent. Res. 90 (2011), 268–272.
176. [176] Kraus, D., Peschel, A., Molecular mechanisms of bacterial resistance to antimicrobial peptides. Curr Top Microbiol Immunol 306 (2006), 231–250.
177. [177] Otto, M., Bacterial evasion of antimicrobial peptides by biofilm formation. Curr Top Microbiol Immunol 306 (2006), 251–258.
178. [178] Groisman, E.A., How bacteria resist killing by host defense peptides. Trends Microbiol. Sci. 2 (1994), 444–448.
179. [179] Peschel, A., Jack, R.W., Otto, M., Collins, L.V., Staubitz, P., Nicholson, G., Kalbacher, H., Nieuwenhuizen, W.F., Jung, G., Tarkowski, A., van Kessel, K.P.M., van Strijp, J.A.G., Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J. Exp Med. 193 (2001), 1067–1076.
180. [180] Nizet, V., Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr. Issues Mol. Biol. 8 (2006), 11–26.
181. [181] Anaya-López, J.L., López-Meza, J.E., Ochoa-Zarzosa, A., Bacterial resistance to cationic antimicrobial peptides. Crit. Rev. Microbiol. 39 (2013), 180–195.
182. [182] Cole, J.N., Nizet, V., Bacterial evasion of host antimicrobial peptide defenses. Microbiol. Spectr., 4, 2016, 10.1128/microbiolspec.VMBF-0006-2015.
183. [183] LaRock, C.N., Nizet, V., Cationic antimicrobial peptide resistance mechanisms of streptococcal pathogens. Biochim. Biophys Acta. 2015 (1848), 3047–3054.
184. [184] Nuri, R., Shprung, T., Shai, Y., Defensive remodeling: How bacterial surface properties and biofilm formation promote resistance to antimicrobial peptides. Biochim. Biophys. Acta. 1848:11 Pt B (2015), 3089–3100.
185. [185] Bauer, M.E., Shafer, W.M., On the in vivo significance of bacterial resistance to antimicrobial peptides. Biochim. Biophys. Acta. 1848:11 Pt B (2015), 3101–3111.
186. [186] Pletzer, D., Coleman, S.R., Hancock, R.E., Anti-biofilm peptides as a new weapon in antimicrobial warfare. Curr. Opin. Microbiol. 33 (2016), 35–40.
187. [187] Miyasaki, K.T., Bodeau, A.L., Ganz, T., Selsted, M.E., Lehrer, R.I., In vitro sensitivity of oral, gram-negative, facultative bacteria to the bactericidal activity of human neutrophil defensins. Infect. Immun. 58 (1990), 3934–3940.
188. [188] Ouhara, K., Komatsuzawa, H., Yamada, S., Shiba, H., Fujiwara, T., Ohara, M., Sayama, K., Hashimoto, K., Kurihara, H., Sugai, M., Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, beta-defensins and LL37, produced by human epithelial cells. J. Antimicrob. Chemother. 55 (2005), 888–896.
189. [189] Sol, A., Ginesin, O., Chaushu, S., Karra, L., Coppenhagen-Glazer, S., Ginsburg, I., Bachrach, G., LL-37 opsonizes and inhibits biofilm formation of Aggregatibacter actinomycetemcomitans at subbactericidal concentrations. Infect. Immun. 81 (2013), 3577–3585.
190. [190] Tew, G.N., Clements, D., Tang, H., Arnt, L., Scott, R.W., Antimicrobial activity of an abiotic host defense peptide mimic. Biochim. Biophys. Acta 1758 (2006), 1387–1392.
191. [191] Wei, G.X., Campagna, A.N., Bobek, L.A., Effect of MUC7 peptides on the growth of bacteria and on Streptococcus mutans biofilm. J. Antimicrob. Chemother. 57 (2006), 1100–1109.
192. [192] Altman, H., Steinberg, D., Porat, Y., Mor, A., Fridman, D., Friedman, M., Bachrach, G., In vitro assessment of antimicrobial peptides as potential agents against several oral bacteria. J. Antimicrob. Chemother. 58 (2006), 198–201.
193. [193] Wang, W., Tao, R., Tong, Z., Ding, Y., Kuang, R., Zhai, S., Liu, J., Ni, L., Effect of a novel antimicrobial peptide chrysophsin-1 on oral pathogens and Streptococcus mutans biofilms. Peptides 33 (2012), 212–219.
194. [194] Concannon, S.P., Crowe, T.D., Abercrombie, J.J., Molina, C.M., Hou, P., Sukumaran, D.K., Rai, P.A., Leung, K.P., Susceptibility of oral bacteria to an antimicrobial decapeptide. J. Med. Microbiol. 52 (2003), 1083–1093.
195. [195] Wilde, C.G., Griffith, J.E., Marra, M.N., Snable, J.L., Scott, R.W., Purification and characterization of human neutrophil peptide 4, a novel member of the defensin family. J. Biol. Chem. 264 (1989), 11200–11203.
196. [196] Shi, Y., Song, W., Feng, Z.H., Zhao, Y.T., Li, F., Tian, Y., Zhao, Y.M., Disinfection of maxillofacial silicone elastomer using a novel antimicrobial agent: recombinant human beta-defensin-3. Eur. J. Clin. Microbiol. Infect Dis. 28 (2009), 415–420.
197. [197] den Hertog, A.L., van Marle, J., van Veen, H.A., Van't Hof, W., Bolscher, J.G., Veerman, E.C., Nieuw Amerongen, A.V., Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. Biochem. J. 388 (2005), 689–695.
198. [198] Pusateri, C.R., Monaco, E.A., Edgerton, M., Sensitivity of Candida albicans biofilm cells grown on denture acrylic to antifungal proteins and chlorhexidine. Arch. Oral Biol. 54 (2009), 588–594.
199. [199] Pathak, S., Chauhan, V.S., Rationale-based, de novo design of dehydrophenylalanine-containing antibiotic peptides and systematic modifi cation in sequence for enhanced potency. Antimicrob. Agents Chemother. 55 (2011), 2178–2188.
200. [200] McLean, D.T., McCrudden, M.T., Linden, G.J., Irwin, C.R., Conlon, J.M., Lundy, F.T., Antimicrobial and immunomodulatory properties of PGLa-AM1, CPF-AM1, and magainin-AM1: potent activity against oral pathogens. Regul. Pept. 194–195 (2014), 63–68.
201. [201] Semlali, A., Leung, K.P., Curt, S., Rouabhia, M., Antimicrobial decapeptide KSL-W attenuates Candida albicans virulence by modulating its effects on Toll-like receptor, human β-defensin, and cytokine expression by engineered human oral mucosa. Peptides 32 (2011), 859–867.
202. [202] Theberge, S., Semlali, A., Alamri, A., Leung, K.P., Rouabhia, M., C. albicans growth, transition, biofilm formation, and gene expression modulation by antimicrobial decapeptide KSL-W. BMC Microbiol., 13, 2013, 246.
203. [203] Shang, D., Liang, H., Wei, S., Yan, X., Yang, Q., Sun, Y., Effects of antimicrobial peptide L-K6, a temporin-1CEb analog on oral pathogen growth, Streptococcus mutans biofilm formation, and anti-inflammatory activity. Appl. Microbiol. Biotechnol. 98 (2014), 8685–8695.
204. [204] Burrows, L.L., Stark, M., Chan, C., Glukhov, E., Sinnadurai, S., Deber, C.M., Activity of novel non-amphipathic cationic antimicrobial peptides against Candida species. J. Antimicrob. Chemother. 57 (2006), 899–907.
205. [205] Liu, V., Dashper, S., Parashos, P., Liu, S.W., Stanton, D., Shen, P., Chivatxaranukul, P., Reynolds, E.C., Antibacterial efficacy of casein-derived peptides against Enterococcus faecalis. Aust. Dent. J. 57 (2012), 339–343.
206. [206] Tao, R., Tong, Z., Lin, Y., Xue, Y., Wang, W., Kuang, R., Wang, P., Tian, Y., Ni, L., Antimicrobial and antibiofilm activity of pleurocidin against cariogenic microorganisms. Peptides 32 (2011), 1748–1754.
207. [207] Padilla, C., Lobos, O., Brevis, P., Abaca, P., Hubert, E., In vitro antibacterial activity of the peptide PsVP-10 against antimicrobial-resistant Enterococcus faecalis isolated from clinical samples. J. Antimicrob. Chemother. 53 (2004), 390–392.
208. [208] Garcia, J.R., Jaumann, F., Schulz, S., Krause, A., Rodríguez-Jiménez, J., Forssmann, U., Adermann, K., Klüver, E., Vogelmeier, C., Becker, D., Hedrich, R., Forssmann, W.G., Bals, R., Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res. 306 (2001), 257–264.
209. [209] Wang, H.Y., Cheng, J.W., Yu, H.Y., Lin, L., Chih, Y.H., Pan, Y.P., Efficacy of a novel antimicrobial peptide against periodontal pathogens in both planktonic and polymicrobial biofilm states. Acta Biomater. 25 (2015), 150–161.
210. [210] Groenink, J., Walgreen-Weterings, E., van ‘t Hof, W., Veerman, E.C., Nieuw Amerongen, A.V., Cationic amphipathic peptides, derived from bovine and human lactoferrins, with antimicrobial activity against oral pathogens. FEMS Microbiol. Lett. 179 (1999), 217–222.
211. [211] Gursoy, U.K., Kononen, E., Luukkonen, N., Uitto, V.J., Human neutrophil defensins and their effect on epithelial cells. J. Periodontol. 84 (2013), 126–133.
212. [212] Raj, P.A., Antonyraj, K.J., Karunakaran, T., Large-scale synthesis and functional elements for the antimicrobial activity of defensins. Biochem. J. 347 (2000), 633–641.
213. [213] Suwandecha, T., Srichana, T., Balekar, N., Nakpheng, T., Pangsomboon, K., Novel antimicrobial peptide specifically active against Porphyromonas gingivalis. Arch. Microbiol. 197 (2015), 899–909.
214. [214] Kelly, C.G., Lehner, T., Peptide inhibitor of Streptococcus mutans in the control of dental caries. Int. J. Pept. Res. Ther. 13 (2007), 517–523.
215. [215] Drobni, M., Li, T., Krüger, C., Loimaranta, V., Kilian, M., Hammarström, L., Jörnvall, H., Bergman, T., Strömberg, N., Host-derived pentapeptide affecting adhesion, proliferation, and local pH in biofilm communities composed of Streptococcus and Actinomyces species. Infect. Immun. 74 (2006), 6293–6299.
216. [216] Dobson, A., O'Connor, P.M., Cotter, P.D., Ross, R.P., Hill, C., Impact of the broad-spectrum antimicrobial peptide, lacticin 3147, on Streptococcus mutans growing in a biofilm and in human saliva. J. Appl. Microbiol. 111 (2011), 1515–1523.
217. [217] Porat, Y., Marynka, K., Tam, A., Steinberg, D., Mor, A., Acyl-substituted dermaseptin S4 derivatives with improved bactericidal properties, including on oral microflora. Antimicrob. Agents Chemother. 50 (2006), 4153–4160.
218. [218] Li, L., He, J., Eckert, R., Yarbrough, D., Lux, R., Anderson, M., Shi, W., Design and characterization of an acid-activated antimicrobial peptide. Chem. Biol. Drug Des. 75 (2010), 127–132.
219. [219] Leung, K.P., Crowe, T.D., Abercrombie, J.J., Molina, C.M., Bradshaw, C.J., Jensen, C.L., Luo, Q., Thompson, G.A., Control of oral biofilm formation by an antimicrobial decapeptide. J. Dent. Res. 84 (2005), 1172–1177.
220. [220] Dashper, S.G., Liu, S.W., Reynolds, E.C., Antimicrobial peptides and their potential as oral therapeutic agents. Int. J. Pept. Res. Ther. 13 (2007), 505–516.
221. [221] Taneja, S., Kumar, P., Malhotra, K., Dhillon, J., Antimicrobial effect of an oxazolidinone, lantibiotic and calcium hydroxide against Enterococcus faecalis biofilm: An in vitro study. Indian J. Dent. 6 (2015), 190–194.
222. [222] Somanath, G., Samant, P.S., Gautam, V., Singh, O.J., Birring, To comparatively evaluate the antimicrobial efficacy of chlorhexidine, nisin and linezolid as an intracanal medicament on Enterococcus faecalis: an in vitro study, Indian. J. Dent. Res. 26 (2015), 613–618.